Srivastava Sudhir Sells 33,333 Shares of SS Innovations International (NASDAQ:SSII) Stock

SS Innovations International, Inc. (NASDAQ:SSII) CEO Srivastava Sudhir sold 33,333 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $3.00, for a total transaction of $99,999.00. Following the completion of the transaction, the chief executive officer owned 108,520,928 shares of the company’s stock, valued at approximately $325,562,784. This represents a 0.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

SS Innovations International Stock Performance

Shares of NASDAQ SSII opened at $3.31 on Friday. The company’s fifty day moving average price is $3.63 and its 200 day moving average price is $4.05. SS Innovations International, Inc. has a 1 year low of $3.11 and a 1 year high of $10.00. The company has a market capitalization of $663.27 million, a PE ratio of -55.17 and a beta of -1.94.

SS Innovations International (NASDAQ:SSII) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.01) EPS for the quarter. SS Innovations International had a negative net margin of 23.73% and a negative return on equity of 26.77%. The firm had revenue of $13.94 million for the quarter.

SS Innovations International News Roundup

Here are the key news stories impacting SS Innovations International this week:

• Positive Sentiment: SS Innovations announced that its robotic technology is being used to bring robotic cardiac surgery to Sri Lanka, supporting the company’s strategy of expanding access to its SSi Mantra system in international markets. SS Innovations Brings Robotic Cardiac Surgery to Sri Lanka
• Positive Sentiment: The company reported 79% growth in SSi Mantra procedures and cited expanding installations, utilization and global reach. Higher procedure volumes could improve recurring revenue potential and validate demand for its robotic-surgery platform. SS Innovations Reports 79% Growth in SSi Mantra Procedures
• Positive Sentiment: Additional milestones include progress in pediatric robotic surgery and telesurgery, which could broaden SSII’s addressable market and strengthen its technology profile if commercial adoption follows. SS Innovations Provides Update on Continuing Progress and Milestones
• Neutral Sentiment: Reported short interest was zero shares, meaning there is no meaningful short position available to create either short-covering support or additional short-selling pressure. The company’s shares remain near their 52-week low and below both the 50-day and 200-day moving averages.
• Negative Sentiment: CEO Sudhir Srivastava sold 33,333 shares for approximately $100,000. The sale reduced his holdings by only 0.03%, but insider selling can modestly weaken investor confidence. SEC Insider Ownership Filing
• Negative Sentiment: SSII continues to report losses, including a recent quarterly loss of $0.01 per share, negative net margin and negative return on equity. Analyst coverage is also broadly bearish, with an average rating of “Sell,” despite a $7 price target from one analyst.

Hedge Funds Weigh In On SS Innovations International

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB grew its position in shares of SS Innovations International by 9.3% in the fourth quarter. Handelsbanken Fonder AB now owns 120,000 shares of the company’s stock valued at $682,000 after purchasing an additional 10,198 shares during the period. Eversept Partners LP raised its position in shares of SS Innovations International by 46.2% during the 1st quarter. Eversept Partners LP now owns 110,157 shares of the company’s stock worth $551,000 after purchasing an additional 34,799 shares during the last quarter. Inspire Investing LLC lifted its stake in SS Innovations International by 26.4% in the 1st quarter. Inspire Investing LLC now owns 104,624 shares of the company’s stock valued at $523,000 after buying an additional 21,851 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in SS Innovations International in the 4th quarter valued at about $284,000. Finally, Geode Capital Management LLC acquired a new stake in SS Innovations International in the 2nd quarter worth about $122,000.

Analyst Upgrades and Downgrades

SSII has been the subject of several recent analyst reports. Wall Street Zen upgraded SS Innovations International from a “sell” rating to a “hold” rating in a research note on Sunday, June 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of SS Innovations International in a research report on Friday, July 17th. Finally, Loop Capital set a $7.00 price objective on SS Innovations International in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, SS Innovations International presently has an average rating of “Sell” and a consensus target price of $7.00.

About SS Innovations International

AVRA Medical Robotics, Inc develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc and changed its name to AVRA Medical Robotics, Inc in November 2015. AVRA Medical Robotics, Inc was founded in 2015 and is based in Orlando, Florida.